Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.

Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide.

This increases biosynthesis of cyclic GMP, resulting in vasodilation.

This drug article relating to the cardiovascular system is a stub.

You can help Wikipedia by expanding it.